Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer Consensus Criteria Conference Paper uri icon


MeSH Major

  • Antifungal Agents
  • Aspergillosis
  • Biomedical Research
  • Candidiasis
  • Coccidioidomycosis
  • Cryptococcosis
  • Histoplasmosis


  • Invasive fungal diseases (IFDs) have become major causes of morbidity and mortality among highly immunocompromised patients. Authoritative consensus criteria to diagnose IFD have been useful in establishing eligibility criteria for antifungal trials. There is an important need for generation of consensus definitions of outcomes of IFD that will form a standard for evaluating treatment success and failure in clinical trials. Therefore, an expert international panel consisting of the Mycoses Study Group and the European Organization for Research and Treatment of Cancer was convened to propose guidelines for assessing treatment responses in clinical trials of IFDs and for defining study outcomes. Major fungal diseases that are discussed include invasive disease due to Candida species, Aspergillus species and other molds, Cryptococcus neoformans, Histoplasma capsulatum, and Coccidioides immitis. We also discuss potential pitfalls in assessing outcome, such as conflicting clinical, radiological, and/or mycological data and gaps in knowledge.


publication date

  • September 2008



  • Conference Paper



  • eng

PubMed Central ID

  • PMC2671230

Digital Object Identifier (DOI)

  • 10.1086/590566

PubMed ID

  • 18637757

Additional Document Info

start page

  • 674

end page

  • 83


  • 47


  • 5